annual CFO:
-$181.39M-$30.28M(-20.04%)Summary
- As of today (June 28, 2025), XENE annual cash flow from operations is -$181.39 million, with the most recent change of -$30.28 million (-20.04%) on December 31, 2024.
- During the last 3 years, XENE annual CFO has fallen by -$111.89 million (-160.98%).
- XENE annual CFO is now -498.02% below its all-time high of $45.57 million, reached on December 31, 2012.
Performance
XENE Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
-$61.65M-$7.27M(-13.36%)Summary
- As of today (June 28, 2025), XENE quarterly cash flow from operations is -$61.65 million, with the most recent change of -$7.27 million (-13.36%) on March 31, 2025.
- Over the past year, XENE quarterly CFO has dropped by -$15.46 million (-33.48%).
- XENE quarterly CFO is now -411.58% below its all-time high of $19.79 million, reached on December 31, 2019.
Performance
XENE quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$196.85M-$15.46M(-8.53%)Summary
- As of today (June 28, 2025), XENE TTM cash flow from operations is -$196.85 million, with the most recent change of -$15.46 million (-8.53%) on March 31, 2025.
- Over the past year, XENE TTM CFO has dropped by -$33.97 million (-20.85%).
- XENE TTM CFO is now -6219.18% below its all-time high of $3.22 million, reached on September 30, 2014.
Performance
XENE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
XENE Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.0% | -33.5% | -20.9% |
| 3 y3 years | -161.0% | -234.6% | -192.8% |
| 5 y5 years | -3747.9% | -371.8% | -2066.8% |
XENE Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -161.0% | at low | -265.5% | at low | -192.8% | at low |
| 5 y | 5-year | -3747.9% | at low | -471.4% | at low | -2066.8% | at low |
| alltime | all time | -498.0% | at low | -411.6% | at low | -6219.2% | at low |
XENE Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$61.65M(+13.4%) | -$196.85M(+8.5%) |
| Dec 2024 | -$181.39M(+20.0%) | -$54.38M(+6.3%) | -$181.39M(+11.7%) |
| Sep 2024 | - | -$51.15M(+72.4%) | -$162.41M(+1.9%) |
| Jun 2024 | - | -$29.67M(-35.8%) | -$159.34M(-2.2%) |
| Mar 2024 | - | -$46.19M(+30.5%) | -$162.89M(+7.8%) |
| Dec 2023 | -$151.11M(+49.6%) | -$35.40M(-26.4%) | -$151.11M(+0.0%) |
| Sep 2023 | - | -$48.08M(+44.7%) | -$151.04M(+13.3%) |
| Jun 2023 | - | -$33.22M(-3.5%) | -$133.36M(+14.0%) |
| Mar 2023 | - | -$34.41M(-2.6%) | -$117.01M(+15.8%) |
| Dec 2022 | -$101.03M(+45.4%) | -$35.33M(+16.2%) | -$101.03M(+16.9%) |
| Sep 2022 | - | -$30.40M(+80.2%) | -$86.41M(+21.7%) |
| Jun 2022 | - | -$16.87M(-8.5%) | -$71.01M(+5.6%) |
| Mar 2022 | - | -$18.43M(-11.0%) | -$67.22M(-3.3%) |
| Dec 2021 | -$69.50M(+44.4%) | -$20.71M(+38.0%) | -$69.50M(+12.3%) |
| Sep 2021 | - | -$15.01M(+14.8%) | -$61.91M(+6.6%) |
| Jun 2021 | - | -$13.08M(-36.9%) | -$58.05M(+4.1%) |
| Mar 2021 | - | -$20.71M(+57.9%) | -$55.77M(+15.9%) |
| Dec 2020 | -$48.12M(+920.9%) | -$13.11M(+17.6%) | -$48.12M(+216.1%) |
| Sep 2020 | - | -$11.15M(+3.4%) | -$15.22M(+36.8%) |
| Jun 2020 | - | -$10.79M(-17.4%) | -$11.13M(+22.5%) |
| Mar 2020 | - | -$13.07M(-166.0%) | -$9.09M(+92.7%) |
| Dec 2019 | -$4.71M | $19.79M(-380.3%) | -$4.71M(-85.1%) |
| Sep 2019 | - | -$7.06M(-19.3%) | -$31.74M(-17.4%) |
| Jun 2019 | - | -$8.75M(+0.6%) | -$38.41M(+9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$8.70M(+20.1%) | -$35.20M(+1.4%) |
| Dec 2018 | -$34.72M(+20.9%) | -$7.24M(-47.2%) | -$34.72M(+1.2%) |
| Sep 2018 | - | -$13.72M(+147.8%) | -$34.32M(+17.4%) |
| Jun 2018 | - | -$5.54M(-32.6%) | -$29.22M(-4.1%) |
| Mar 2018 | - | -$8.22M(+20.2%) | -$30.48M(+6.1%) |
| Dec 2017 | -$28.73M(+46.8%) | -$6.84M(-20.7%) | -$28.73M(+8.2%) |
| Sep 2017 | - | -$8.63M(+26.8%) | -$26.56M(+18.3%) |
| Jun 2017 | - | -$6.80M(+5.3%) | -$22.46M(+6.5%) |
| Mar 2017 | - | -$6.46M(+38.3%) | -$21.08M(+7.7%) |
| Dec 2016 | -$19.57M(+8.1%) | -$4.67M(+3.2%) | -$19.57M(-2.9%) |
| Sep 2016 | - | -$4.52M(-16.7%) | -$20.14M(-1.8%) |
| Jun 2016 | - | -$5.43M(+9.8%) | -$20.50M(+17.2%) |
| Mar 2016 | - | -$4.94M(-5.8%) | -$17.50M(-3.3%) |
| Dec 2015 | -$18.10M(-6905.6%) | -$5.25M(+7.4%) | -$18.10M(+14.5%) |
| Sep 2015 | - | -$4.88M(+101.5%) | -$15.81M(+240.8%) |
| Jun 2015 | - | -$2.42M(-56.3%) | -$4.64M(+4.5%) |
| Mar 2015 | - | -$5.55M(+88.0%) | -$4.44M(-1768.8%) |
| Dec 2014 | $266.00K(-108.0%) | -$2.95M(-147.0%) | $266.00K(-91.7%) |
| Sep 2014 | - | $6.28M(-382.4%) | $3.22M(-204.9%) |
| Jun 2014 | - | -$2.23M(+164.3%) | -$3.07M(+264.3%) |
| Mar 2014 | - | -$842.00K | -$842.00K |
| Dec 2013 | -$3.32M(-107.3%) | - | - |
| Dec 2012 | $45.57M(-432.9%) | - | - |
| Dec 2011 | -$13.69M | - | - |
FAQ
- What is Xenon Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals annual CFO year-on-year change?
- What is Xenon Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals quarterly CFO year-on-year change?
- What is Xenon Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals TTM CFO year-on-year change?
What is Xenon Pharmaceuticals annual cash flow from operations?
The current annual CFO of XENE is -$181.39M
What is the all time high annual CFO for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high annual cash flow from operations is $45.57M
What is Xenon Pharmaceuticals annual CFO year-on-year change?
Over the past year, XENE annual cash flow from operations has changed by -$30.28M (-20.04%)
What is Xenon Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of XENE is -$61.65M
What is the all time high quarterly CFO for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high quarterly cash flow from operations is $19.79M
What is Xenon Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, XENE quarterly cash flow from operations has changed by -$15.46M (-33.48%)
What is Xenon Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of XENE is -$196.85M
What is the all time high TTM CFO for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high TTM cash flow from operations is $3.22M
What is Xenon Pharmaceuticals TTM CFO year-on-year change?
Over the past year, XENE TTM cash flow from operations has changed by -$33.97M (-20.85%)